Want to see KR:000520 full AI Analyst Report?
Samil Pharmaceutical Co., Ltd. (000520) Financial Statements
Samil Pharmaceutical Co., Ltd. Financial Overview
Samil Pharmaceutical Co., Ltd.'s market cap is currently $164.86B. The company's EPS TTM is $-1763.67; its P/E ratio is -4.34; and it has a dividend yield of 0.96%. Samil Pharmaceutical Co., Ltd. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 210.37B | $ 219.70B | $ 196.35B | $ 179.68B | $ 134.25B |
| Gross Profit | $ 67.44B | $ 80.91B | $ 72.21B | $ 67.49B | $ 48.99B |
| Operating Income | $ -23.94B | $ 113.04M | $ 6.47B | $ 4.02B | $ 399.74M |
| EBITDA | $ -10.72B | $ 8.71B | $ 10.34B | $ 10.31B | $ 6.15B |
| Net Income | $ -34.59B | $ -5.63B | $ 1.66B | $ -28.29M | $ -5.35B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 6.41B | $ 5.14B | $ 906.14M | $ 1.90B | $ 15.26B |
| Total Assets | $ 371.60B | $ 395.07B | $ 370.68B | $ 356.70B | $ 226.40B |
| Total Debt | $ 164.02B | $ 150.08B | $ 175.88B | $ 159.26B | $ 125.51B |
| Net Debt | $ 157.61B | $ 144.94B | $ 174.97B | $ 157.35B | $ 121.52B |
| Total Liabilities | $ 238.34B | $ 218.95B | $ 242.85B | $ 230.88B | $ 160.66B |
| Stockholders' Equity | $ 133.26B | $ 176.12B | $ 127.83B | $ 125.82B | $ 65.75B |
| Cash Flow | |||||
| Free Cash Flow | $ -13.52B | $ -3.02B | $ -12.65B | $ -44.50B | $ -31.67B |
| Operating Cash Flow | $ -6.06B | $ 2.59B | $ 11.75B | $ 4.15B | $ 1.42B |
| Investing Cash Flow | $ -7.98B | $ -6.36B | $ -19.78B | $ -35.94B | $ -45.31B |
| Financing Cash Flow | $ 15.29B | $ 7.98B | $ 8.48B | $ 29.71B | $ 31.87B |
Currency in KRW